SCHEMBL21754477

SCHEMBL21754477

CN1CCCC(CCC(=O)ON2C(=O)CCC2=O)C1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CHRNB2 P17787 1/20 0.36
▸ CHRNB4 P30926 1/20 0.36
▸ CHRNA3 P32297 1/20 0.36
▸ CHRNA4 P43681 1/20 0.36
▸ L3MBTL1 Q9Y468 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ GFER P55789 1/20 0.34
▸ MGLL Q99685 1/20 0.34
▸ PSMB8 P28062 1/20 0.34
▸ MAOA P21397 1/20 0.32
▸ MAOB P27338 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21754480 0.86 SMN1; SMN2 (0.40) SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL24593481 0.83 L3MBTL1 (0.41) SMN1; SMN2L3MBTL1ALDH1A1PSMB8
SCHEMBL9752033 0.83 L3MBTL1 (0.41) SMN1; SMN2L3MBTL1ALDH1A1PSMB8
SCHEMBL22897324 0.82 SMN1; SMN2 (0.39) SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL14559362 0.77 KMT2A (0.37) SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL24622843 0.74 NAAA (0.47) PSMB8
SCHEMBL21253844 0.73 SMN1; SMN2 (0.44) SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL21664445 0.73 NAAA (0.49) PSMB8
SCHEMBL15171758 0.73 SMN1; SMN2 (0.45) SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL22009028 0.73 BRD4 (0.39) SMN1; SMN2ALDH1A1MGLLBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10568976-B2 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents DEBRECENI EGYETEM (HU) 2020-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10568976-B2 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents SLC39A14, SLC39A11, TMEM14C SMN1; SMN2 880/4885CHRNB2 1502/4885CHRNB4 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback